Ibodutant 10 mg

DRUG3 trials

Sponsors

Menarini Group

Conditions

Irritable Bowel Syndrome With Diarrhea

Phase 3

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

CompletedNCT02107196

Menarini GroupIrritable Bowel Syndrome With Diarrhea

Start: 2014-03-31End: 2015-06-30Updated: 2017-01-19

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

TerminatedNCT02120027

Menarini GroupIrritable Bowel Syndrome With Diarrhea

Start: 2014-02-28End: 2015-11-30Updated: 2017-03-03

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

WithdrawnNCT02320318

Menarini GroupIrritable Bowel Syndrome With Diarrhea

Start: 2015-10-31End: 2016-12-31Updated: 2016-05-19